The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Author

  • Åke Borg
  • Bo Baldetorp
  • Mårten Fernö
  • Dick Killander
  • Håkan Olsson
  • Stefan Ryden
  • Helgi Sigurdsson

Summary, in English

Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.

Department/s

  • Breastcancer-genetics

Publishing year

1994

Language

English

Pages

137-144

Publication/Series

Cancer Letters

Volume

81

Issue

2

Document type

Journal article

Publisher

Elsevier

Topic

  • Cancer and Oncology

Keywords

  • ERBB2
  • HER-2/neu
  • Gene amplification
  • Breast cancer
  • Adjuvant tamoxifen
  • Therapy resistance

Status

Published

ISBN/ISSN/Other

  • ISSN: 1872-7980